Floatz logo

Osimertinib

Acute Leukemia of Ambiguous Lineage

Syndax PharmaceuticalsSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Acute Leukemia of Ambiguous Lineage cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
METHOTREXATE
SWOG Cancer Research Network
Phase 2B
Cytosin-Arabinosid
SWOG Cancer Research Network
Phase 2B
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2B
Fludarabine
Janssen Research & Development, LLC
Phase 2B

View all 48 →

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →